Changes in Central Corneal Thickness over Time. The Ocular Hypertension Treatment Study

James D Brandt, Mae O. Gordon, Julia A. Beiser, Shan C. Lin, Monica Y. Alexander, Michael A. Kass

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Objective: To describe how much change, if any, occurs between central corneal thickness (CCT) measurements performed an average of 3.8 years apart in participants in the Ocular Hypertension Treatment Study (OHTS) and to identify clinical and demographic factors that are associated with changes in CCT, including baseline intraocular presure, duration and class of ocular hypotensive medication, medical history, and systemic medication. Design: Secondary analysis of data from a randomized clinical trial. Participants: Ocular Hypertension Treatment Study participants. Participants who had undergone incisional intraocular or keratorefractive surgery between CCT measurements were excluded. Testing: The first CCT measurements were performed starting in 1999, and the second measurements were performed starting in 2002. Measurements were performed by OHTS certified technicians using an ultrasonic pachymeter under a standardized protocol. Main Outcome Measure: Central corneal thickness measurement (micrometers). Results: First and second CCT measurements were available from 73% (1191) of the 1636 OHTS participants randomized. Central corneal thickness decreased a mean rate of -0.74±3.5 μm/year between the first and second CCT measurements. The mean medication exposure between first and second CCT measurements in participants originally randomized to observation (n = 595) was 1.1±1.6 years, versus 5.0±2.7 years in participants originally randomized to medication (n = 596). Central corneal thickness decreased by a mean of 1.0±3.4 μm/year among participants originally randomized to observation, compared with 0.5±3.5 μm/year among participants originally randomized to medication (P<0.0001). Subgroup analyses suggest that participants treated only with topical prostaglandin analogues (PGAs) between the two CCT measurements had a greater rate of decrease per year than participants treated only with topical β-blockers. Conclusions: The rate of CCT decrease over 3.8 years is comparable to the cross-sectional age differences reported in the OHTS at the first measurement (0.6 μm/year) and comparable to other cross-sectional studies. Use of topical PGAs may be associated with a slightly higher rate of thinning. The modest age- and drug-related rates of thinning observed are unlikely to influence tonometry or clinical decision-making substantially in most clinical situations. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references.

Original languageEnglish (US)
JournalOphthalmology
Volume115
Issue number9
DOIs
StatePublished - Sep 2008

Fingerprint

Corneal Pachymetry
Ocular Hypertension
Synthetic Prostaglandins
Disclosure
Observation
Manometry
Ultrasonics
Randomized Controlled Trials
Cross-Sectional Studies
Demography
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Changes in Central Corneal Thickness over Time. The Ocular Hypertension Treatment Study. / Brandt, James D; Gordon, Mae O.; Beiser, Julia A.; Lin, Shan C.; Alexander, Monica Y.; Kass, Michael A.

In: Ophthalmology, Vol. 115, No. 9, 09.2008.

Research output: Contribution to journalArticle

Brandt, James D ; Gordon, Mae O. ; Beiser, Julia A. ; Lin, Shan C. ; Alexander, Monica Y. ; Kass, Michael A. / Changes in Central Corneal Thickness over Time. The Ocular Hypertension Treatment Study. In: Ophthalmology. 2008 ; Vol. 115, No. 9.
@article{9e1bb767bb4c4c15bbdce7e9aa4ffede,
title = "Changes in Central Corneal Thickness over Time. The Ocular Hypertension Treatment Study",
abstract = "Objective: To describe how much change, if any, occurs between central corneal thickness (CCT) measurements performed an average of 3.8 years apart in participants in the Ocular Hypertension Treatment Study (OHTS) and to identify clinical and demographic factors that are associated with changes in CCT, including baseline intraocular presure, duration and class of ocular hypotensive medication, medical history, and systemic medication. Design: Secondary analysis of data from a randomized clinical trial. Participants: Ocular Hypertension Treatment Study participants. Participants who had undergone incisional intraocular or keratorefractive surgery between CCT measurements were excluded. Testing: The first CCT measurements were performed starting in 1999, and the second measurements were performed starting in 2002. Measurements were performed by OHTS certified technicians using an ultrasonic pachymeter under a standardized protocol. Main Outcome Measure: Central corneal thickness measurement (micrometers). Results: First and second CCT measurements were available from 73{\%} (1191) of the 1636 OHTS participants randomized. Central corneal thickness decreased a mean rate of -0.74±3.5 μm/year between the first and second CCT measurements. The mean medication exposure between first and second CCT measurements in participants originally randomized to observation (n = 595) was 1.1±1.6 years, versus 5.0±2.7 years in participants originally randomized to medication (n = 596). Central corneal thickness decreased by a mean of 1.0±3.4 μm/year among participants originally randomized to observation, compared with 0.5±3.5 μm/year among participants originally randomized to medication (P<0.0001). Subgroup analyses suggest that participants treated only with topical prostaglandin analogues (PGAs) between the two CCT measurements had a greater rate of decrease per year than participants treated only with topical β-blockers. Conclusions: The rate of CCT decrease over 3.8 years is comparable to the cross-sectional age differences reported in the OHTS at the first measurement (0.6 μm/year) and comparable to other cross-sectional studies. Use of topical PGAs may be associated with a slightly higher rate of thinning. The modest age- and drug-related rates of thinning observed are unlikely to influence tonometry or clinical decision-making substantially in most clinical situations. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references.",
author = "Brandt, {James D} and Gordon, {Mae O.} and Beiser, {Julia A.} and Lin, {Shan C.} and Alexander, {Monica Y.} and Kass, {Michael A.}",
year = "2008",
month = "9",
doi = "10.1016/j.ophtha.2008.02.001",
language = "English (US)",
volume = "115",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - Changes in Central Corneal Thickness over Time. The Ocular Hypertension Treatment Study

AU - Brandt, James D

AU - Gordon, Mae O.

AU - Beiser, Julia A.

AU - Lin, Shan C.

AU - Alexander, Monica Y.

AU - Kass, Michael A.

PY - 2008/9

Y1 - 2008/9

N2 - Objective: To describe how much change, if any, occurs between central corneal thickness (CCT) measurements performed an average of 3.8 years apart in participants in the Ocular Hypertension Treatment Study (OHTS) and to identify clinical and demographic factors that are associated with changes in CCT, including baseline intraocular presure, duration and class of ocular hypotensive medication, medical history, and systemic medication. Design: Secondary analysis of data from a randomized clinical trial. Participants: Ocular Hypertension Treatment Study participants. Participants who had undergone incisional intraocular or keratorefractive surgery between CCT measurements were excluded. Testing: The first CCT measurements were performed starting in 1999, and the second measurements were performed starting in 2002. Measurements were performed by OHTS certified technicians using an ultrasonic pachymeter under a standardized protocol. Main Outcome Measure: Central corneal thickness measurement (micrometers). Results: First and second CCT measurements were available from 73% (1191) of the 1636 OHTS participants randomized. Central corneal thickness decreased a mean rate of -0.74±3.5 μm/year between the first and second CCT measurements. The mean medication exposure between first and second CCT measurements in participants originally randomized to observation (n = 595) was 1.1±1.6 years, versus 5.0±2.7 years in participants originally randomized to medication (n = 596). Central corneal thickness decreased by a mean of 1.0±3.4 μm/year among participants originally randomized to observation, compared with 0.5±3.5 μm/year among participants originally randomized to medication (P<0.0001). Subgroup analyses suggest that participants treated only with topical prostaglandin analogues (PGAs) between the two CCT measurements had a greater rate of decrease per year than participants treated only with topical β-blockers. Conclusions: The rate of CCT decrease over 3.8 years is comparable to the cross-sectional age differences reported in the OHTS at the first measurement (0.6 μm/year) and comparable to other cross-sectional studies. Use of topical PGAs may be associated with a slightly higher rate of thinning. The modest age- and drug-related rates of thinning observed are unlikely to influence tonometry or clinical decision-making substantially in most clinical situations. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references.

AB - Objective: To describe how much change, if any, occurs between central corneal thickness (CCT) measurements performed an average of 3.8 years apart in participants in the Ocular Hypertension Treatment Study (OHTS) and to identify clinical and demographic factors that are associated with changes in CCT, including baseline intraocular presure, duration and class of ocular hypotensive medication, medical history, and systemic medication. Design: Secondary analysis of data from a randomized clinical trial. Participants: Ocular Hypertension Treatment Study participants. Participants who had undergone incisional intraocular or keratorefractive surgery between CCT measurements were excluded. Testing: The first CCT measurements were performed starting in 1999, and the second measurements were performed starting in 2002. Measurements were performed by OHTS certified technicians using an ultrasonic pachymeter under a standardized protocol. Main Outcome Measure: Central corneal thickness measurement (micrometers). Results: First and second CCT measurements were available from 73% (1191) of the 1636 OHTS participants randomized. Central corneal thickness decreased a mean rate of -0.74±3.5 μm/year between the first and second CCT measurements. The mean medication exposure between first and second CCT measurements in participants originally randomized to observation (n = 595) was 1.1±1.6 years, versus 5.0±2.7 years in participants originally randomized to medication (n = 596). Central corneal thickness decreased by a mean of 1.0±3.4 μm/year among participants originally randomized to observation, compared with 0.5±3.5 μm/year among participants originally randomized to medication (P<0.0001). Subgroup analyses suggest that participants treated only with topical prostaglandin analogues (PGAs) between the two CCT measurements had a greater rate of decrease per year than participants treated only with topical β-blockers. Conclusions: The rate of CCT decrease over 3.8 years is comparable to the cross-sectional age differences reported in the OHTS at the first measurement (0.6 μm/year) and comparable to other cross-sectional studies. Use of topical PGAs may be associated with a slightly higher rate of thinning. The modest age- and drug-related rates of thinning observed are unlikely to influence tonometry or clinical decision-making substantially in most clinical situations. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references.

UR - http://www.scopus.com/inward/record.url?scp=50249116726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50249116726&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2008.02.001

DO - 10.1016/j.ophtha.2008.02.001

M3 - Article

C2 - 18378313

AN - SCOPUS:50249116726

VL - 115

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 9

ER -